(Q34091131)

30 July 2017

0 references

1 reference

title

Genus Phyllanthus for chronic hepatitis B virus infection: a systematic review (English)

1 reference

30 July 2017

1 reference

1 reference

1 reference

1 reference

Liu J

1

1 reference

30 July 2017

Lin H

series ordinal

2

1 reference

30 July 2017

McIntosh H

series ordinal

3

1 reference

30 July 2017

publication date

1 September 2001

1 reference

Journal of Viral Hepatitis

30 July 2017

published in

1 reference

30 July 2017

volume

8

1 reference

30 July 2017

issue

5

1 reference

30 July 2017

page(s)

358-366

1 reference

The discovery of the hepatitis viruses

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00307.X

Current therapeutic trends in therapy for chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00307.X

Effects of an extract from Phyllanthus niruri on hepatitis B and woodchuck hepatitis viruses: in vitro and in vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00307.X

Differential inhibition of reverse transcriptase and cellular DNA polymerase-alpha activities by lignans isolated from Chinese herbs, Phyllanthus myrtifolius Moon, and tannins from Lonicera japonica Thunb and Castanopsis hystrix.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00307.X

Phyllanthus amarus down-regulates hepatitis B virus mRNA transcription and replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00307.X

Phyllanthus amarus suppresses hepatitis B virus by interrupting interactions between HBV enhancer I and cellular transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00307.X

Phyllanthus amarus and hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00307.X

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00307.X

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00307.X

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00307.X

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00307.X

Do certain countries produce only positive results? A systematic review of controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00307.X

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00307.X

Failure of Phyllanthus amarus to eradicate hepatitis B surface antigen from symptomless carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00307.X

10.1046/J.1365-2893.2001.00307.X

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference